Concern regarding risk of late thrombosis after "off-label" treatment with drug-eluting stents has prompted increased use of bare-metal stents (BMS) in current practice. The sequelae of late BMS failures, however, have been poorly characterized. METHODS AND RESULTS: We performed a retrospective study of 4503 consecutive patients treated with at least 1 BMS and dual antiplatelet therapy between 1994 and 2000. The cumulative incidence of stent thrombosis was 0.5% at 30 days (95% CI, 0.3% to 0.7%), 0.8% at 1 year (95% CI, 0.6% to 1.1%), and 2.0% at 10 years (95% CI, 1.5% to 2.5%). Risk of late (30 days to 1 year) and very late (>1 year) BMS thrombosis was increased among patients considered off label for drug-eluting stent use (P=0.024). When saphenous vein graft interventions were excluded, however, risk after off-label use was not significantly increased (P=0.23). Other correlates included vein graft intervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.001). Mortality was markedly increased after late and very late BMS thrombosis, particularly during the first 30 days (hazard ratios, 22 [95% CI, 3.1 to 159] and 40 [95% CI, 15 to 107], respectively). The 10-year incidence of clinical restenosis was 18.1% (95% CI, 16.5% to 19.7%), presenting with MI in 2.1% (95% CI, 1.6% to 2.6%). Restenosis presenting with MI was associated with increased mortality compared with no restenosis (hazard ratio, 2.37; P<0.001) and with restenosis with a non-MI presentation (hazard ratio, 2.42; P<0.001). CONCLUSIONS: The incidence of BMS thrombosis and of MI caused by restenosis during extended follow-up is significant. Both complications are associated with mortality.

Division of Cardiovascular Diseases Department of Internal Medicine Mayo Clinic College of Medicine Rochester

Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents

Komentář [k článku Dlouhodobé výsledky implantace nepokrytých metalických stentů.

000      

00000naa 2200000 a 4500

001      

bmc07513906

003      

CZ-PrNML

005      

20111210124744.0

008      

081215s2008 xr e cze||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a cze $b eng

044    __

$a xr

100    1_

$a Doyle, B.

245    10

$a Dlouhodobé výsledky implantace nepokrytých metalických stentů / $c Doyle B, et al.

246    11

$a Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents

314    __

$a Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester

520    9_

$a Concern regarding risk of late thrombosis after "off-label" treatment with drug-eluting stents has prompted increased use of bare-metal stents (BMS) in current practice. The sequelae of late BMS failures, however, have been poorly characterized. METHODS AND RESULTS: We performed a retrospective study of 4503 consecutive patients treated with at least 1 BMS and dual antiplatelet therapy between 1994 and 2000. The cumulative incidence of stent thrombosis was 0.5% at 30 days (95% CI, 0.3% to 0.7%), 0.8% at 1 year (95% CI, 0.6% to 1.1%), and 2.0% at 10 years (95% CI, 1.5% to 2.5%). Risk of late (30 days to 1 year) and very late (>1 year) BMS thrombosis was increased among patients considered off label for drug-eluting stent use (P=0.024). When saphenous vein graft interventions were excluded, however, risk after off-label use was not significantly increased (P=0.23). Other correlates included vein graft intervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.001). Mortality was markedly increased after late and very late BMS thrombosis, particularly during the first 30 days (hazard ratios, 22 [95% CI, 3.1 to 159] and 40 [95% CI, 15 to 107], respectively). The 10-year incidence of clinical restenosis was 18.1% (95% CI, 16.5% to 19.7%), presenting with MI in 2.1% (95% CI, 1.6% to 2.6%). Restenosis presenting with MI was associated with increased mortality compared with no restenosis (hazard ratio, 2.37; P<0.001) and with restenosis with a non-MI presentation (hazard ratio, 2.42; P<0.001). CONCLUSIONS: The incidence of BMS thrombosis and of MI caused by restenosis during extended follow-up is significant. Both complications are associated with mortality.

650    _2

$a senioři $7 D000368

650    _2

$a balónková koronární angioplastika $x škodlivé účinky $x trendy $7 D015906

650    _2

$a kohortové studie $7 D015331

650    _2

$a koronární restenóza $x epidemiologie $x etiologie $x mortalita $7 D023903

650    _2

$a koronární trombóza $x epidemiologie $x etiologie $x mortalita $7 D003328

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a kovy $x škodlivé účinky $7 D008670

650    _2

$a lidé středního věku $7 D008875

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a stenty $x škodlivé účinky $x trendy $7 D015607

650    _2

$a časové faktory $7 D013997

650    _2

$a výsledek terapie $7 D016896

773    0_

$w MED00012706 $t Clinical cardiology alert $g Roč. 2, č. 3 (2008), s. 18 $x 1213-2586

787    18

$w bmc07513907 $i Recenze v: $t Komentář [k článku Dlouhodobé výsledky implantace nepokrytých metalických stentů

910    __

$a ABA008 $b B 2242 $c 407 a $y 1

990    __

$a 20081212145120 $b ABA008

991    __

$a 20090106095835 $b ABA008

999    __

$a ok $b bmc $g 629501 $s 481956

BAS    __

$a 3

BMC    __

$a 2008 $b 2 $c 3 $d 18 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706

LZP    __

$a 2008-23/mkme